On the CGI-I scale , the analysis revealed that MPH was more effective than ATX and GXR .
For any adverse events , RBX ( 89 % ) was the safest alternative .
Network meta- analysis offered a broader overview on the available treatments for ADHD , especially for safety issues , and contributes towards evidence gathering and clinical practice decisions .
The aim of this study is to gather evidence of head-to-head double-blind r and omized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents .
Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
OBJECTIVE To compare the dose effects of long-acting extended-release dexmethylpheni date ( ER d-MPH ) and ER mixed amphetamine salts ( ER MAS ) on attention-deficit/hyperactivity disorder ( ADHD ) symptom dimensions , global and specific impairments , and common adverse events associated with stimulants . METHODS Fifty-six children and adolescents with ADHD participated in an 8-week , double-blind , crossover study comparing ER d-MPH ( 10 , 20 , 25 - 30 mg ) and ER MAS ( 10 , 20 , 25 - 30 ) with a week of r and omized placebo within each drug period . Efficacy was assessed with the ADHD Rating Scale-IV ( ADHD-RS-IV ) , whereas global and specific domains of impairment were assessed with the Clinical Global Impressions Severity and Improvement Scales and the parent-completed Weiss Functional Impairment Scale , respectively . Insomnia and decreased appetite , common stimulant-related adverse events , were measured with the parent-completed Stimulant Side Effects Rating Scale . RESULTS Both ER d-MPH and ER MAS were associated with significant reductions in ADHD symptoms . Improvement in Total ADHD and Hyperactivity/Impulsivity symptoms were strongly associated with increasing dose , whereas improvements in Inattentive symptoms were only moderately associated with dose . About 80 % demonstrated reliable change on ADHD-RS-IV at the highest dose level of ER MAS compared with 79 % when receiving ER d-MPH .  Decreased appetite and insomnia were more common at higher dose levels for both stimulants . Approximately 43 % of the responders were preferential responders to only one of the stimulant formulations . CONCLUSIONS Dose level , rather than stimulant class , was strongly related to medication response
On the CGI-I scale , the analysis revealed that MPH was more effective than ATX and GXR .
For any adverse events , RBX ( 89 % ) was the safest alternative .
Network meta- analysis offered a broader overview on the available treatments for ADHD , especially for safety issues , and contributes towards evidence gathering and clinical practice decisions .
The aim of this study is to gather evidence of head-to-head double-blind r and omized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents .